肝素诱导性血小板减少症中超大免疫复合物的调控
本研究探讨是否可通过联合磺达肝癸钠抑制PF4-肝素相互作用及人源化抗PF4单克隆抗体(hRTO)阻断PF4四聚体形成来调控肝素诱导性血小板减少症(HIT)抗原与超大免疫复合物(ULIC)的形成和稳定性。结果显示,两药联合在低于各自单用有效浓度下即可抑制HIT抗原形成、促进抗原解离、抑制ULIC形成并促进其解聚,并阻断Fcγ受体依赖的因子Xa活性诱导及全血中人血小板活化。
要点
- 磺达肝癸钠联合hRTO在低于各自单用有效浓度下抑制HIT抗原形成并促进其解离。
- 联合方案抑制ULIC形成并促进ULIC解聚,阻断Fcγ受体依赖的血小板活化。
- 磺达肝癸钠可转变为阻断ULIC形成的疾病特异性干预,原文认为可能提高疗效。
核心结论
- HIT抗原和免疫复合物是动态的、可被调控的。
- 磺达肝癸钠可从作用于下游放大步骤的抗凝药转变为阻断ULIC形成的合理疾病特异性干预。
- 预防ULIC形成和稳定性的干预可能提高疗效、允许使用更低剂量、缩短抗血栓治疗持续时间并帮助预防这一严重血栓性疾病。
研究设计与样本
- 体外实验研究,检测磺达肝癸钠联合人源化抗PF4单克隆抗体(hRTO)对HIT抗原和ULIC形成与稳定性的影响。
- 使用单核细胞THP1细胞检测Fcγ受体依赖的因子Xa活性诱导,并在全血中检测人血小板活化。
主要发现
- 磺达肝癸钠联合hRTO在低于各自单用有效浓度下抑制HIT抗原形成、促进抗原解离、抑制ULIC形成并促进ULIC解聚。
- 联合方案阻断单核细胞THP1细胞中Fcγ受体依赖的因子Xa活性诱导及全血中人血小板活化。
- 与hRTO联合时,磺达肝癸钠在等于或低于临床用于抑制FXa凝血活性的浓度下抑制HIT抗原和免疫复合物形成及Fcγ受体介导的活化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a serious thrombotic disorder caused by ultralarge immune complexes (ULICs) containing platelet factor 4 (PF4) and heparin that form the HIT antigen, together with a subset of anti-PF4 antibodies. ULICs initiate prothrombotic responses by engaging Fcγ receptors on platelets, neutrophils, and monocytes. Contemporary anti-thrombotic therapy for HIT is neither entirely safe nor entirely successful and acts downstream of ULIC formation and Fcγ receptor-initiated generation of thrombin. OBJECTIVES: To determine whether HIT antigen and ULIC formation and stability could be modified favorably by inhibiting PF4-heparin interactions with fondaparinux, together with blocking formation of PF4 tetramers using a humanized monoclonal anti-PF4 antibody (hRTO). METHODS: Results: The combination of fondaparinux and hRTO inhibited HIT antigen formation, promoted antigen dissociation, inhibited ULIC formation, and promoted ULIC disassembly at concentrations below the effective concentration of either alone and blocked Fcγ receptor-dependent induction of factor Xa activity by monocytic THP1 cells and activation of human platelets in whole blood. Combined with hRTO, fondaparinux inhibited HIT antigen and immune complex formation and activation through Fcγ receptors at concentrations at or below those used clinically to inhibit FXa coagulant activity. CONCLUSIONS: HIT antigen and immune complexes are dynamic and amenable to modulation. Fondaparinux can be converted from an anticoagulant that acts at a downstream amplification step into a rationale, disease-specific intervention that blocks ULIC formation. Interventions that prevent ULIC formation and stability might increase the efficacy, permit use of lower doses, shorten the duration of antithrombotic therapy, and help prevent this serious thrombotic disorder.
引用
- Cai Z, Bdeir K, Yarovoi SV, et al. Modulation of ultralarge immune complexes in heparin-induced thrombocytopenia. J Thromb Haemost. 2022. PMID: 36696211. doi:10.1016/j.jtha.2022.11.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。